Day 3 Recap: Fall Clinical 2024

Author(s):

Emma Andrus, Associate Editor

Key Takeaways

Leqselvi tablets demonstrate significant scalp hair regrowth in severe alopecia areata patients, indicating long-term efficacy.
Tralokinumab achieves high EASI-75 and IGA 0/1 rates, confirming its safety and efficacy for moderate-to-severe atopic dermatitis.
Lebrikizumab shows efficacy in reducing eczema severity and itch in patients who discontinued dupilumab.
Rocatinlimab improves SCORAD scores in adults with moderate to severe atopic dermatitis, as presented at Fall Clinical 2024.

Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Long-Term Results Demonstrate Clinically Meaningful Improvements in Hair Regrowth Following Oral Deuruxolitinib

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Final ECZTEND Study Results Confirm Long-Term Safety and Efficacy of Tralokinumab for Moderate-to-Severe Atopic Dermatitis

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Exploring Advancements in Palmoplantar Pustulosis, Psoriasis Comorbidities, and Phototherapy

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Lebrikizumab Demonstrates Efficacy in Itch and Skin Clearance Among Patients With AD Who Discontinued Dupilumab

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Innovative Insights in Skin Cancer Prognosis, Gene Expression Profiling, and Early Career Tips

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Raj Chovatiya, MD, PhD: Current Disease States and Early Career Controversies

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic and eczema and early career controversies.

Rocatinlimab Improves SCORAD in Adults With Moderate to Severe AD

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

To view all conference coverage from Fall Clinical 2024, click here.